Conclusions Whole flaxseed , but not flaxseed oil and lignan extract , has significant effects on improving glycemic control .
Context The results of human clinical trials investigating the effects of flaxseed on glucose control and insulin sensitivity are inconsistent .
Objective The present study aim ed to systematic ally review and analyze r and omized controlled trials assessing the effects of flaxseed consumption on glycemic control .
Flaxseed Lignan Complex Administration in Older Human Type 2 Diabetics Manages Central Obesity and Prothrombosis—An Invitation to Further Investigation into Polypharmacy Reduction
Aim . Animal and human study evidence supports the hypothesis that flaxseed lignan complex ( FLC ) at a dose of 600 mg secoisolariciresinol diglucoside (SDG)/day for three months would combat hyperglycaemia , dyslipidemia , blood pressure , central obesity , prothrombotic state , inflammation , and low density lipoprotein ( LDL ) oxidation . Methods . Sixteen type 2 diabetic patients completed this double-blind , r and omised crossover placebo-controlled study . A univariate repeated measures analysis of covariance ( significance P < 0.05 ) was followed by a mixed linear model effects analysis corrected for multiple comparisons ( MCC ) . Results . Prior to MCC , FLC caused decreased fasting plasma glucose , A1c , inflammation ( c-reactive protein ( CRP ) and interleukin-6 ( IL-6 ) ) , and increased bleeding time . After correction for multiple comparisons , FLC induced a statistically significant increase in bleeding time and smaller waist circumference gain . No treatment effect occurred in the other variables before or after adjustment . Conclusions . It is concluded that FLC significantly increased bleeding time thus reducing the prothrombotic state , reduced central obesity gain as measured by waist circumference , and did not affect significantly the other dependent variables measured after adjustment for multiple comparisons . These findings , not yet published in human type 2 diabetes , suggest that this FLC dose over at least three months , may , subject to further investigation , reduce polypharmacy
Conclusions Whole flaxseed , but not flaxseed oil and lignan extract , has significant effects on improving glycemic control .
Context The results of human clinical trials investigating the effects of flaxseed on glucose control and insulin sensitivity are inconsistent .
Objective The present study aim ed to systematic ally review and analyze r and omized controlled trials assessing the effects of flaxseed consumption on glycemic control .